Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

By making cancer cells suicidal and turning them against ... particularly for cancers with unclear therapeutic targets, combination therapies are frequently used to combat resistance.

Bennu also contains all five amino acids that make up terrestrial genetic material. The NASA mission with the Osiris-Rex probe , which collected samples on Bennu and dropped them over the Earth in ...

WASHINGTON — Two-thirds of animal and plant populations are declining in genetic diversity, which makes it harder to adapt to environmental changes, according to research published Wednesday.

Rutgers Health researchers have discovered that brain immune cells from people with a high genetic risk for alcohol use disorder (AUD) behave differently than cells from low-risk people when exposed ...

While the launch is in its early stages, with over 50 treatment centers activated globally and more than 50 patients having initiated cell ... for Vertex? Casgevy, Vertex's gene therapy treatment, ...